Drugs Information:
Eculizumab
Basic Information
|
||
| ID | DDInter618 | |
| Drug Type | biotech | |
| Protein Chemical Formula | None | |
| Protein Average Weight | 148000.000 | |
| CAS Number | 219685-50-4 | |
| Description | Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.[L6919] | |
| ATC Classification | L04AA25 | |
| Sequences | None | |
| Useful Links | DrugBank PubChem Substance PharmGKB Therapeutic Targets Database Wikipedia ChEMBL | |
Interactions with
Eculizumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|